4-Isopropoxymethyl-[1,3]dioxolane | 17226-23-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氧戊环
• 英文名称: 4-Isopropoxymethyl-[1,3]dioxolane
• 英文别名: 4-{[(Propan-2-yl)oxy]methyl}-1,3-dioxolane；4-(propan-2-yloxymethyl)-1,3-dioxolane
• CAS: 17226-23-2
• 化学式: C₇H₁₄O₃
• 分子量: 146.186
• InChiKey: XQXZTEGVRIBJNR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  10
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  27.7
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-Isopropoxymethyl-[1,3]dioxolane 、 三乙基硅烷 生成 Triethyl-(3-isopropoxy-2-methoxy-propoxy)-silane
  参考文献：
  名称：

  MIRONOV, I. V.;MELNITSKIJ, I. A.;SIRAEVA, I. N.;KILADZE, T. K.;KANTOR, E.+, ZH. OBSHCH. XIMII, 1982, 52, N 10, 2284-2288

  摘要：

  DOI：

文献信息

• PYRROLIDINYL UREA, PYRROLIDINYL THIOUREA AND PYRROLIDINYL GUANIDINE COMPOUNDS AS TRKA KINASE INHIBITORS
  申请人：Allen Shelley

  公开号：US20150166564A1

  公开（公告）日：2015-06-18

  Compounds of Formula I: or stereoisomers, tautomers, or pharmaceutically acceptable salts, or solvates or prodrugs thereof, where R 1 , R 2 , R a , R b , R c , R d , X, Y, B, and Ring C are as defined herein, and wherein the Y—B moiety and the NH—C(═X)—NH moiety are in the trans configuration, are inhibitors of TrkA kinase and are useful in the treatment of diseases which can be treated with a TrkA kinase inhibitor such as pain, cancer, inflammation, neurodegenerative diseases and certain infectious diseases.

  化合物I的公式：或其立体异构体、互变异构体、药学上可接受的盐、溶剂或前药，其中R1、R2、Ra、Rb、Rc、Rd、X、Y、B和环C的定义如本文所述，其中Y-B基团和NH-C（═X）-NH基团处于反式构象，是TrkA激酶的抑制剂，可用于治疗可以通过TrkA激酶抑制剂治疗的疾病，例如疼痛、癌症、炎症、神经退行性疾病和某些传染病。
• POLYHYDROXYURETHANE MICROPARTICLES, AND PROCESS FOR PRODUCING SAME
  申请人：Dainichiseika Color & Chemicals Mfg. Co., Ltd.

  公开号：EP2706078A1

  公开（公告）日：2014-03-12

  A problem is to provide polyhydroxyurethane microparticles, which have a narrow particle size distribution and are applicable to a wide range of use. Provided are polyhydroxyurethane microparticles which are spherical polymer microparticles having particle sizes of 0.1 µm to 300 µm. A polymer that makes up the polymer microparticles has in a structure thereof chemical structure units represented by the following formula (1) and/or chemical structure units represented by the following formula (2). In the chemical structure units (1) and (2), -O-CO- bonds have been derived from carbon dioxide.

  目前的问题是提供粒径分布窄且适用范围广的聚羟基聚氨酯微粒。本发明提供的聚羟基聚氨酯微粒是球形聚合物微粒，其粒径为 0.1 微米至 300 微米。构成聚合物微粒的聚合物在其结构中具有下式（1）表示的化学结构单元和/或下式（2）表示的化学结构单元。在化学结构单元（1）和（2）中，-O-CO-键来自二氧化碳。
• Mironov, I. V.; Mel'nitskii, I. A.; Siraeva, I. N., Journal of general chemistry of the USSR, 1982, vol. 52, # 10, p. 2034 - 2037
  作者：Mironov, I. V.、Mel'nitskii, I. A.、Siraeva, I. N.、Kiladze, T. K.、Kantor, E. A.、Rakhmankulov, D. L.

  DOI：——

  日期：——
• PYRROLIDINYL UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS AS TRKA KINASE INHIBITORS
  申请人：ARRAY BIOPHARMA INC.

  公开号：US20160297796A1

  公开（公告）日：2016-10-13

  Compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts, or solvates or prodrugs thereof, where R 1 , R 2 , R a , R b , R c , R d , X, Ring B, and Ring C are as defined herein, and wherein Ring B moiety and the NH—C(═X)—NH moiety are in the trans configuration, are inhibitors of TrkA kinase and are useful in the treatment of diseases which can be treated with a TrkA kinase inhibitor such as pain, cancer, inflammation/inflammatory diseases, neurodegenerative diseases, certain infectious diseases, Sjogren's syndrome, endometriosis, diabetic peripheral neuropathy, prostatitis and pelvic pain syndrome.
• N-BICYCLIC ARYL,N'-PYRAZOLYL UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS AS TRKA KINASE INHIBITORS
  申请人：ARRAY BIOPHARMA INC.

  公开号：US20160280681A1

  公开（公告）日：2016-09-29

  Compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein Ring A, Ring C and X are as defined herein, are inhibitors of TrkA kinase and are useful in the treatment of diseases which can be treated with a TrkA kinase inhibitor such as pain, cancer, inflammation/inflammatory diseases, neurodegenerative diseases, certain infectious diseases, Sjogren's syndrome, endometriosis, diabetic peripheral neuropathy, prostatitis or pelvic pain syndrome.